Pegfilgrastim biosimilar - Sandoz

Drug Profile

Pegfilgrastim biosimilar - Sandoz

Alternative Names: LA-EP2006

Latest Information Update: 11 Sep 2015

Price : $50

At a glance

  • Originator Sandoz
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Febrile neutropenia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 May 2015 Phase-III is still ongoing for Febrile neutropenia in Russia and USA
  • 31 Dec 2013 Sandoz completes the phase III PROTECT 2 trial in Febrile neutropenia prevention in patients with breast cancer undergoing myelosuppressive chemotherapy in USA, Argentina, Chile, India, Malaysia, Puerto Rico, Russia and Spain (NCT01516736)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top